Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

P/FCFE
Price to FCFE

6 537.1
Current
274.8
Median
23.4
Industry
Higher than median
Higher than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
6 537.1
=
Market Cap
525.8m INR
/
FCFE
80.4k INR
All Countries
Close
Market Cap P/FCFE
IN
Transgene Biotek Ltd
BSE:526139
525.8m INR 6 537.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 231 766.6
US
Abbvie Inc
NYSE:ABBV
316.5B USD 12.8
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 24
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 11.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD -79.5
US
Epizyme Inc
F:EPE
94.1B EUR -424.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 76.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 23.7
US
Seagen Inc
F:SGT
39.3B EUR -58.4
NL
argenx SE
XBRU:ARGX
36B EUR -113.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More